As its role in cancer immunology has been elucidated, pharmacological STING agonists that induce antitumor immunity have been investigated.[41, 42] However, numerous cancers have developed strategies for evading innate immune surveillance, particularly by suppressing the cGAS–STING pathway. Here, STING1 is linked to cancer.